๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Inflammatory Marker and Pre-existing Venous Fibrosis to Predict AVF Mal-maturation

RecruitingNAAges 20 Years - anyAllNational Taiwan University Hospital
NCT05136859 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

End-stage renal disease patients needs a functional vascular access to receive hemodialysis and prolong their lives. Arteriovenous fistula (AVF) is priority consideration for hemodialysis, which is a connecting a superficial vein to a nearby artery and allowing this vein to enlarge and increase in internal diameter under arterial circulation. Unfortunately, 30-50% of fistulae fail to mature. Vascular calcification and stenosis were considered for early failure. The perivascular fat of artery can be predicted successful AVF maturation. However, Few previous studies have compared AVF maturation between perivascular the fat of cephalic vein or removal during the AVF surgery. This study evaluated whether the effect of AVF inflammation and preexisting vascular fibrosis is associated to perivascular the fat of cephalic vein. Investigators will also verify inflammation by analysis of blood and

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age of 20 and older adult patients. 2. preoperatively clinical and ultrasound assessment of the arm vessels are visible for the creation of a native HDAVF that include๏ผšthe augmented diameters of the veins is \> 2.0 mm and the diameter of the radial artery is\> 2.0 mm. Besides, there is no obvious stenosis of vessels in the forearm. Exclusion Criteria: 1. The patient refused to join the study 2. serious heart failure (Physicians identify insufficient cardiac output that may affect sacral blood flow development after surgery) 3. Unconsciousness 4. Bedridden for long time 5. systemic lupus erythematosus(SLE), or other known autoimmune diseases 6. The physician excludes the possibility of creating a wrist HDAVF before surgery 7. Surgeon preoperatively identifies vessel inadequacy for the creation of a wrist HDAVF 8. Choose a site other than the wrist for surgery 9. Unexpected complications happen during the surgery that prevent the completion of a wrist HDAVF
๐Ÿ’Š

What it tests

  • preserve
๐Ÿ“

Where

1 site
National Taiwan University Hospital
Taipei, Taiwan
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy